Slingshot Insights | Atra Overview

ATRA Overview

Upcoming Projects (ATRA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ATRA)

Understanding the future of Allogeneic T cell therapy after the EU approval of Atara's Ebvallo
Ticker: ATRA
Executed On: Mar 14, 2023 at 05:00 PM EDT
A look at pending data update from ATA188 and potential in multiple sclerosis.
Ticker: ATRA
Executed On: Apr 22, 2022 at 10:00 AM EDT

Upcoming & Overdue Catalysts (ATRA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ATRA)

FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Ticker: ATRA
Occurred on: Dec 29, 2017

Strategic Initiatives (ATRA)

Atara Bio (ATRA) Announces Clinical Trial Collaboration with Merck (MRK) Evaluating ATA129 + Keytruda in Patients with Platinum-Resistant or Recurrent EBV-Associated Nasopharyngeal Carcinoma (NPC)
Tickers: ATRA, MRK
Announcement Date: Apr 21, 2017